See page 7 for analyst certification and important disclosures, including non-US analyst disclosures. Overweight J P M O R G A N Asia Pacific Equity Research 21 July 2026 Telix Pharmaceuticals 2Q26 acceleration skews FY26 revenue risk to upside; regulatory catalysts now key; Overweight TLX reported its 2Q26 update today. Overall, PSMA Imaging continues to perform ahead of consensus (+5% at 1H26) and we see clear upside risk to the FY26 guidance range (now pointing to the upper-end of US$950-970m). While a U ...